EPRX Eupraxia Pharmaceuticals Forecast, Technical & Fundamental Analysis
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals... Show more
EPRX is expected to report earnings to rise 5.46% to -23 cents per share on November 11
Q3'26
Est.
$-0.23
Q2'26
Est.
$-0.22
Q1'26
Missed
by $0.05
Q4'25
Missed
by $0.17
Q3'25
Missed
by $0.01
The last earnings report on August 11 showed earnings per share of -22 cents, beating the estimate of -22 cents. With 128.42K shares outstanding, the current market capitalization sits at 451.31M.
A.I.dvisor tells us that EPRX and LCTX have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EPRX and LCTX's prices will move in lockstep.
EPRX in upward trend: price rose above 50-day moving average on August 03, 2026
EPRX moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend. In of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on EPRX as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for EPRX just turned positive on July 31, 2026. Looking at past instances where EPRX's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .
The 10-day moving average for EPRX crossed bullishly above the 50-day moving average on August 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where EPRX advanced for three days, in of 110 cases, the price rose further within the following month. The odds of a continued upward trend are .
EPRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 120 cases where EPRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.167) is normal, around the industry mean (20.109). P/E Ratio (0.000) is within average values for comparable stocks, (24.032). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.929). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (445.198).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. EPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
